Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA).
Alwin SebastianKornelis S M van der GeestFiona CoathPrisca GondoAbdul KayaniCraig MackernessBernard HadebeSue InnesJo JacksonBhaskar DasguptaPublished in: BMC rheumatology (2020)
The identification of prognostic factors in GCA is both timely and needed. A prognostic marker, such as the HS, could help to stratify GCA patients for an appropriate treatment regimen. Tocilizumab, an IL-6R blocking agent, switches off the acute phase response (C-Reactive Protein), making it difficult to measure the disease activity. Therefore, an independent HS, and changes in that score during treatment and follow-up, maybe a more objective measure of response compare to patient-reported symptoms and clinical assessment alone.
Keyphrases
- prognostic factors
- disease activity
- patient reported
- rheumatoid arthritis
- rheumatoid arthritis patients
- giant cell
- systemic lupus erythematosus
- juvenile idiopathic arthritis
- end stage renal disease
- ankylosing spondylitis
- ejection fraction
- lymph node
- chronic kidney disease
- newly diagnosed
- neoadjuvant chemotherapy
- radiation therapy
- combination therapy
- sentinel lymph node
- locally advanced